You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTapentadol
Accession NumberDB06204
TypeSmall Molecule
GroupsApproved
DescriptionOpioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008.
Structure
Thumb
Synonyms
BN-200
CG-5503
Nucynta
Tapentadol
External Identifiers
  • R331333
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nucyntatablet, film coated100 mg/1oralbryant ranch prepack2009-06-01Not applicableUs
Nucyntatablet, film coated100 mg/1oralStat Rx USA2009-06-01Not applicableUs
Nucyntatablet, film coated75 mg/1oralJanssen Pharmaceuticals, Inc.2009-06-01Not applicableUs
Nucyntatablet50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-29Not applicableUs
Nucyntatablet, film coated75 mg/1oralPhysicians Total Care, Inc.2010-03-19Not applicableUs
Nucyntatablet, film coated50 mg/1oralStat Rx USA2009-06-01Not applicableUs
Nucyntatablet, film coated100 mg/1oralJanssen Pharmaceuticals, Inc.2009-06-01Not applicableUs
Nucyntatablet, film coated75 mg/1oralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-13Not applicableUs
Nucyntatablet, film coated100 mg/1oralPhysicians Total Care, Inc.2010-03-19Not applicableUs
Nucyntasolution20 mg/mLoralJanssen Pharmaceuticals, Inc.2012-10-15Not applicableUs
Nucyntatablet, film coated75 mg/1oralSTAT Rx USA LLC2009-06-01Not applicableUs
Nucyntatablet, film coated100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-06-01Not applicableUs
Nucyntatablet, film coated50 mg/1oralbryant ranch prepack2009-06-01Not applicableUs
Nucyntatablet, film coated50 mg/1oralJanssen Pharmaceuticals, Inc.2009-06-01Not applicableUs
Nucyntatablet, film coated50 mg/1oralRebel Distributors Corp2009-06-01Not applicableUs
Nucyntatablet, film coated50 mg/1oralPhysicians Total Care, Inc.2010-03-19Not applicableUs
Nucynta CRtablet (extended-release)200 mgoralJanssen Inc2011-02-172014-12-04Canada
Nucynta CRtablet (extended-release)50 mgoralJanssen Inc2011-02-172014-08-19Canada
Nucynta CRtablet (extended-release)250 mgoralJanssen Inc2011-02-172015-03-25Canada
Nucynta CRtablet (extended-release)100 mgoralJanssen Inc2011-02-172014-08-19Canada
Nucynta CRtablet (extended-release)150 mgoralJanssen Inc2011-02-172014-09-30Canada
Nucynta ERtablet, film coated, extended release100 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release150 mg/1oralJanssen Pharmaceuticals, Inc.2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release50 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release200 mg/1oralJanssen Pharmaceuticals, Inc.2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release250 mg/1oralJanssen Pharmaceuticals, Inc.2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release50 mg/1oralJanssen Pharmaceuticals, Inc.2011-08-25Not applicableUs
Nucynta ERtablet, film coated, extended release100 mg/1oralJanssen Pharmaceuticals, Inc.2011-08-25Not applicableUs
Nucynta Extended-releasetablet (extended-release)250 mgoralJanssen Inc2014-04-16Not applicableCanada
Nucynta Extended-releasetablet (extended-release)50 mgoralJanssen Inc2014-04-16Not applicableCanada
Nucynta Extended-releasetablet (extended-release)100 mgoralJanssen Inc2014-04-16Not applicableCanada
Nucynta Extended-releasetablet (extended-release)150 mgoralJanssen Inc2014-04-16Not applicableCanada
Nucynta Extended-releasetablet (extended-release)200 mgoralJanssen Inc2014-04-16Not applicableCanada
Nucynta Irtablet (immediate release)50 mgoralJanssen Inc2012-03-20Not applicableCanada
Nucynta Irtablet (immediate release)75 mgoralJanssen Inc2012-03-20Not applicableCanada
Nucynta Irtablet (immediate release)100 mgoralJanssen Inc2012-03-20Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PalexiaGrünenthal Ltd
TAPAL MSN Labs
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Tapentadol Hydrochloride
Thumb
  • InChI Key: ZELFLGGRLLOERW-YECZQDJWSA-N
  • Monoisotopic Mass: 257.154642102
  • Average Mass: 257.799
DBSALT000169
Categories
UNIIH8A007M585
CAS number175591-23-8
WeightAverage: 221.3385
Monoisotopic: 221.177964363
Chemical FormulaC14H23NO
InChI KeyInChIKey=KWTWDQCKEHXFFR-SMDDNHRTSA-N
InChI
InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
IUPAC Name
3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol
SMILES
CC[[email protected]]([C@@H](C)CN(C)C)C1=CC(O)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenylpropane
  • Aralkylamine
  • Phenol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationThe immediate-release formulation of tapentadol is indicated for the relief of moderate to severe acute pain. The long-acting formulation serves as a continuous, around-the-clock analgesic that is indicated for the relief of moderate to severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy.
PharmacodynamicsTapentadol is a centrally-acting synthetic analgesic. It is 18 times less potent than morphine in terms of binding to human mu-opioid receptors. It also increases norepinephrine concentrations in the brains of rats via inhibition of norepinephrine reuptake. Selective mu-opioid antagonists like naloxone can block analgesia from tapentadol. It also has not effect on the QT interval.
Mechanism of actionTapendadol causes large increases in levels of extracellular norepinephrine (NE) due to a dual mechanism of action involving mu opioid receptor (MOR) agonism as well as noradrenaline reuptake inhibition.
Related Articles
AbsorptionBioavailability, immediate release (IR), 86 mg: 32%; Bioavailability, extended release (ER), 86 mg: 32%; Cmax, IR: 64.2 ng/mL; Cmax, ER: 22.5 ng/mL; T max, IR: 1.5 hours; T max, ER: 5.0 hours; Tapentadol accumulates following multiple repeat doses.
Volume of distribution

Following IV administration, volume of distribution is 540 ± 98 L.

Protein binding~20%
Metabolism

97% of the dose is metabolized mostly via conjugation with glucuronic acid to produce glucuronides. Tapentadol is also metabolized into N-desmethyl tapentadol (13%) by CYP2C9 and CYP 2C19. CYP2D6 is involved in the formation of the metabolite, hydroxy tapentadol (2%). All metabolites are inactive.

SubstrateEnzymesProduct
Tapentadol
Not Available
N-desmethyl tapentadolDetails
Route of eliminationTapentadol and its metabolites are excreted almost exclusively (99%) via the kidneys. Approximately 70% (55% O-glucuronide and 15% sulfate of tapentadol) is excreted in conjugated form. A total of 3% of drug was excreted in urine as unchanged drug.
Half lifeElimination half-life, IV: 4 hours.
Clearance

Total clearance = 1530 ± 177 ml/min.

ToxicityOral, rabbit: LD50 = 3200 mg/kg; Oral, mouse: LD50 = 300 mg/kg; Oral, rat: LD50: 980 mg/kg; The most common reasons for discontinuation due to adverse events were dizziness, nausea, vomiting, somnolence, and headache.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier+0.9232
Caco-2 permeable+0.7912
P-glycoprotein substrateSubstrate0.559
P-glycoprotein inhibitor INon-inhibitor0.9304
P-glycoprotein inhibitor IINon-inhibitor0.9408
Renal organic cation transporterNon-inhibitor0.6918
CYP450 2C9 substrateNon-substrate0.8085
CYP450 2D6 substrateNon-substrate0.5219
CYP450 3A4 substrateSubstrate0.5509
CYP450 1A2 substrateInhibitor0.6665
CYP450 2C9 inhibitorNon-inhibitor0.8856
CYP450 2D6 inhibitorNon-inhibitor0.5538
CYP450 2C19 inhibitorNon-inhibitor0.921
CYP450 3A4 inhibitorNon-inhibitor0.8389
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8875
Ames testNon AMES toxic0.6862
CarcinogenicityNon-carcinogens0.5177
BiodegradationNot ready biodegradable0.9421
Rat acute toxicity2.6035 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7187
hERG inhibition (predictor II)Inhibitor0.6155
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Solutionoral20 mg/mL
Tabletoral50 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral50 mg/1
Tablet, film coatedoral75 mg/1
Tablet, film coated, extended releaseoral100 mg/1
Tablet, film coated, extended releaseoral150 mg/1
Tablet, film coated, extended releaseoral200 mg/1
Tablet, film coated, extended releaseoral250 mg/1
Tablet, film coated, extended releaseoral50 mg/1
Tablet (extended-release)oral100 mg
Tablet (extended-release)oral150 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral250 mg
Tablet (extended-release)oral50 mg
Tablet (immediate release)oral100 mg
Tablet (immediate release)oral50 mg
Tablet (immediate release)oral75 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6071970 No1997-06-062017-06-06Us
US7994364 No2005-06-272025-06-27Us
US8075872 No2003-11-202023-11-20Us
US8114383 No2004-10-102024-10-10Us
US8309060 No2003-11-202023-11-20Us
US8420056 No2003-11-202023-11-20Us
US8536130 No2008-09-222028-09-22Us
USRE39593 No2002-08-052022-08-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.87 FDA label
pKa9.34 - 10.45 FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.78 mg/mLALOGPS
logP3.47ALOGPS
logP2.96ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.28ChemAxon
pKa (Strongest Basic)9.6ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area23.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.56 m3·mol-1ChemAxon
Polarizability26.58 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Giuseppe Motta, Domenico Vergani, Giorgio Bertolini, “PROCESS FOR THE PREPARATION OF TAPENTADOL AND INTERMEDIATES THEREOF.” U.S. Patent US20120232306, issued September 13, 2012.

US20120232306
General References
  1. Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. [PubMed:17656655 ]
  2. Gohler K, Brett M, Smit JW, Rengelshausen J, Terlinden R: Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013 Apr;51(4):338-48. doi: 10.5414/CP201722. [PubMed:23357834 ]
  3. Xu XS, Smit JW, Lin R, Stuyckens K, Terlinden R, Nandy P: Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. 2010 Oct;49(10):671-82. doi: 10.2165/11535390-000000000-00000. [PubMed:20818833 ]
External Links
ATC CodesN02AX06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (666 KB)
MSDSDownload (481 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tapentadol.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Tapentadol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Tapentadol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Tapentadol is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe metabolism of Tapentadol can be decreased when combined with Abiraterone.
AcepromazineAcepromazine may increase the hypotensive activities of Tapentadol.
AcepromazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Aceprometazine.
AcetazolamideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Acetophenazine.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Tapentadol.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Tapentadol.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Tapentadol.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Tapentadol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Tapentadol.
AlimemazineAlimemazine may increase the hypotensive activities of Tapentadol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Tapentadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Tapentadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Tapentadol.
AlvimopanThe risk or severity of adverse effects can be increased when Tapentadol is combined with Alvimopan.
AmilorideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Amiloride.
AmiodaroneThe metabolism of Tapentadol can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Tapentadol.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Tapentadol which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Tapentadol.
AmoxapineTapentadol may increase the serotonergic activities of Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Tapentadol.
AmperozideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Tapentadol.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Tapentadol.
AprepitantThe metabolism of Tapentadol can be increased when combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Tapentadol is combined with Aripiprazole.
ArmodafinilThe metabolism of Tapentadol can be decreased when combined with Armodafinil.
ArtemetherThe metabolism of Tapentadol can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Tapentadol.
AsenapineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Asenapine.
AtomoxetineThe metabolism of Tapentadol can be decreased when combined with Atomoxetine.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Tapentadol.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Tapentadol.
AzaperoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Azaperone.
AzelastineTapentadol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Tapentadol.
AzosemideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Tapentadol.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Tapentadol.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Tapentadol.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Tapentadol is combined with Benmoxin.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Tapentadol.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Tapentadol.
BenzphetamineBenzphetamine may increase the analgesic activities of Tapentadol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Tapentadol.
BetaxololThe metabolism of Tapentadol can be decreased when combined with Betaxolol.
BifeprunoxThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bifeprunox.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Tapentadol.
BortezomibThe metabolism of Tapentadol can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Tapentadol is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
BrimonidineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Tapentadol.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Tapentadol.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Tapentadol.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Tapentadol.
BumetanideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Tapentadol.
BuprenorphineBuprenorphine may decrease the analgesic activities of Tapentadol.
BuprenorphineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Buprenorphine.
BupropionThe metabolism of Tapentadol can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Tapentadol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Tapentadol.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Tapentadol.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Tapentadol.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Tapentadol.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Tapentadol.
ButorphanolButorphanol may decrease the analgesic activities of Tapentadol.
ButorphanolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Tapentadol.
Canrenoic acidThe risk or severity of adverse effects can be increased when Tapentadol is combined with Canrenoic acid.
CapecitabineThe metabolism of Tapentadol can be decreased when combined with Capecitabine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tapentadol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Tapentadol.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Tapentadol.
CariprazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Tapentadol.
CaroxazoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Caroxazone.
CelecoxibThe metabolism of Tapentadol can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Tapentadol can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Tapentadol.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Tapentadol.
ChloramphenicolThe metabolism of Tapentadol can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Tapentadol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Tapentadol.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tapentadol.
ChloroquineThe metabolism of Tapentadol can be decreased when combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Tapentadol.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Tapentadol.
ChlorphentermineChlorphentermine may increase the analgesic activities of Tapentadol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Tapentadol.
ChlorpromazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tapentadol.
CholecalciferolThe metabolism of Tapentadol can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Tapentadol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Tapentadol can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Tapentadol.
CitalopramTapentadol may increase the serotonergic activities of Citalopram.
CitalopramThe metabolism of Tapentadol can be decreased when combined with Citalopram.
ClemastineThe metabolism of Tapentadol can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Tapentadol.
ClobazamThe metabolism of Tapentadol can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Tapentadol is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Tapentadol.
ClomipramineTapentadol may increase the serotonergic activities of Clomipramine.
ClomipramineThe metabolism of Tapentadol can be decreased when combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Tapentadol.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Tapentadol.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Tapentadol.
ClotrimazoleThe metabolism of Tapentadol can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Clozapine.
ClozapineThe metabolism of Tapentadol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Tapentadol can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Tapentadol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Tapentadol.
ConivaptanThe risk or severity of adverse effects can be increased when Tapentadol is combined with Conivaptan.
CyamemazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Tapentadol.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tapentadol.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tapentadol.
CyclosporineThe metabolism of Tapentadol can be decreased when combined with Cyclosporine.
CyclothiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Tapentadol.
DabrafenibThe serum concentration of Tapentadol can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tapentadol.
DapiprazoleThe risk or severity of adverse effects can be increased when Tapentadol is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tapentadol.
DapoxetineTapentadol may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Tapentadol.
DarunavirThe serum concentration of Tapentadol can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of Tapentadol can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Tapentadol.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Tapentadol.
DesipramineThe metabolism of Tapentadol can be decreased when combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Tapentadol.
DesmopressinThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Tapentadol.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Tapentadol.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Tapentadol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tapentadol.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Tapentadol.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tapentadol.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Tapentadol.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Tapentadol.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Tapentadol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Tapentadol.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Tapentadol.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Tapentadol.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tapentadol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Tapentadol.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Tapentadol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Tapentadol.
DiphenhydramineThe metabolism of Tapentadol can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Tapentadol.
DolasetronDolasetron may decrease the analgesic activities of Tapentadol.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Tapentadol.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Tapentadol.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
DoxylamineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Tapentadol.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
DronedaroneThe metabolism of Tapentadol can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Tapentadol.
DuloxetineThe metabolism of Tapentadol can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Duloxetine.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Tapentadol.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Tapentadol.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Tapentadol.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tapentadol.
EfonidipineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Efonidipine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Tapentadol.
EliglustatThe metabolism of Tapentadol can be decreased when combined with Eliglustat.
EluxadolineTapentadol may increase the constipating activities of Eluxadoline.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Tapentadol.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Tapentadol.
EplerenoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Eplerenone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Tapentadol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tapentadol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Tapentadol.
EscitalopramTapentadol may increase the serotonergic activities of Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tapentadol.
Eslicarbazepine acetateThe metabolism of Tapentadol can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Tapentadol can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Tapentadol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Tapentadol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid.
EthanolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Tapentadol.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Tapentadol.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Tapentadol.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Tapentadol.
EthoxzolamideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Tapentadol.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tapentadol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Tapentadol.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Tapentadol.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Tapentadol.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Tapentadol.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tapentadol.
EtoperidoneTapentadol may increase the serotonergic activities of Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Tapentadol.
EtravirineThe metabolism of Tapentadol can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Tapentadol.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Tapentadol.
FencamfamineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fencamfamine.
FenfluramineTapentadol may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Tapentadol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Tapentadol.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Tapentadol.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Tapentadol.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Tapentadol.
FloxuridineThe metabolism of Tapentadol can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Tapentadol can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Tapentadol.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Tapentadol.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Tapentadol.
FluorouracilThe metabolism of Tapentadol can be decreased when combined with Fluorouracil.
FluoxetineTapentadol may increase the serotonergic activities of Fluoxetine.
FluoxetineThe metabolism of Tapentadol can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Tapentadol.
FluphenazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Tapentadol.
FluspirileneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Tapentadol.
FluvastatinThe metabolism of Tapentadol can be decreased when combined with Fluvastatin.
FluvoxamineTapentadol may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Tapentadol can be decreased when combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Tapentadol.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Tapentadol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Tapentadol.
FurazolidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furazolidone.
FurosemideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Furosemide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Tapentadol.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Tapentadol is combined with gabapentin enacarbil.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Tapentadol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Tapentadol.
GemfibrozilThe metabolism of Tapentadol can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Tapentadol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Tapentadol.
GranisetronGranisetron may decrease the analgesic activities of Tapentadol.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Tapentadol.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Tapentadol.
HaloperidolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Haloperidol.
HaloperidolThe metabolism of Tapentadol can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Tapentadol.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Tapentadol.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tapentadol.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tapentadol.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Tapentadol.
HydracarbazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydracarbazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Tapentadol.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Tapentadol.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Tapentadol.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
HydroxyzineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Tapentadol.
IloperidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iloperidone.
ImipramineThe metabolism of Tapentadol can be decreased when combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Imipramine.
IndalpineTapentadol may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Indapamide.
IndinavirThe metabolism of Tapentadol can be decreased when combined with Indinavir.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tapentadol.
IproclozideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Tapentadol is combined with Iproniazid.
IrbesartanThe metabolism of Tapentadol can be decreased when combined with Irbesartan.
IsocarboxazidThe risk or severity of adverse effects can be increased when Tapentadol is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Tapentadol.
IsoniazidThe metabolism of Tapentadol can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Isosorbide.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Tapentadol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tapentadol.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Tapentadol.
KetoconazoleThe metabolism of Tapentadol can be decreased when combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Tapentadol is combined with KW-3902.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Tapentadol.
LeflunomideThe metabolism of Tapentadol can be decreased when combined with Leflunomide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Tapentadol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Tapentadol.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Tapentadol.
LevocetirizineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Tapentadol.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Tapentadol.
LevomilnacipranTapentadol may increase the serotonergic activities of Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tapentadol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Tapentadol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Tapentadol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Tapentadol.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Tapentadol.
LithiumThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Tapentadol.
LopinavirThe metabolism of Tapentadol can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Tapentadol.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Tapentadol.
LorcaserinThe metabolism of Tapentadol can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lorcaserin.
LosartanThe metabolism of Tapentadol can be decreased when combined with Losartan.
LovastatinThe metabolism of Tapentadol can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Loxapine.
Lu AA21004Tapentadol may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Tapentadol.
LuliconazoleThe serum concentration of Tapentadol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Tapentadol can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Tapentadol can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Tapentadol is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tapentadol.
MebanazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mebanazine.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Tapentadol.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Tapentadol.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Tapentadol.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Tapentadol.
MelperoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Tapentadol.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Tapentadol.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tapentadol.
MersalylThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Tapentadol.
MesoridazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tapentadol.
MethadoneThe metabolism of Tapentadol can be decreased when combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Tapentadol.
MethamphetamineMethamphetamine may increase the analgesic activities of Tapentadol.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Tapentadol.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tapentadol.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Tapentadol.
MethazolamideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tapentadol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Tapentadol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Tapentadol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Tapentadol.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tapentadol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methyclothiazide.
Methylene blueThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methylene blue.
Methylene blueMethylene blue may increase the hypotensive activities of Tapentadol.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Tapentadol.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Tapentadol.
MetoclopramideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metoclopramide.
MetolazoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Tapentadol.
MetoprololThe metabolism of Tapentadol can be decreased when combined with Metoprolol.
MetyrosineTapentadol may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Tapentadol.
MifepristoneThe serum concentration of Tapentadol can be increased when it is combined with Mifepristone.
MilnacipranTapentadol may increase the serotonergic activities of Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Tapentadol.
MinaprineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
MirabegronThe metabolism of Tapentadol can be decreased when combined with Mirabegron.
MirtazapineTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tapentadol.
MoclobemideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Moclobemide.
MoclobemideThe metabolism of Tapentadol can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Tapentadol can be decreased when combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Tapentadol.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Tapentadol.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Tapentadol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.
NabiloneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nabilone.
NalbuphineNalbuphine may decrease the analgesic activities of Tapentadol.
NalbuphineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nalbuphine.
NaltrexoneThe therapeutic efficacy of Tapentadol can be decreased when used in combination with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Tapentadol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Tapentadol.
NelfinavirThe metabolism of Tapentadol can be decreased when combined with Nelfinavir.
NevirapineThe metabolism of Tapentadol can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nialamide.
NicardipineThe metabolism of Tapentadol can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Tapentadol can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Tapentadol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Tapentadol.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Tapentadol.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Tapentadol.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Tapentadol.
OctamoxinThe risk or severity of adverse effects can be increased when Tapentadol is combined with Octamoxin.
OlanzapineTapentadol may increase the serotonergic activities of Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Tapentadol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tapentadol.
OmeprazoleThe metabolism of Tapentadol can be decreased when combined with Omeprazole.
OndansetronOndansetron may decrease the analgesic activities of Tapentadol.
OndansetronThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Tapentadol.
OrphenadrineTapentadol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Tapentadol.
OsanetantThe risk or severity of adverse effects can be increased when Tapentadol is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tapentadol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Tapentadol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Tapentadol.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Tapentadol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Tapentadol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Tapentadol.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Tapentadol.
PaliperidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Paliperidone.
PalonosetronPalonosetron may decrease the analgesic activities of Tapentadol.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tapentadol.
PanobinostatThe metabolism of Tapentadol can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Tapentadol can be decreased when combined with Pantoprazole.
ParaldehydeTapentadol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Tapentadol.
PargylineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pargyline.
ParoxetineTapentadol may increase the serotonergic activities of Paroxetine.
ParoxetineThe metabolism of Tapentadol can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Tapentadol.
PentazocinePentazocine may decrease the analgesic activities of Tapentadol.
PentazocineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Tapentadol.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Tapentadol.
PerampanelThe risk or severity of adverse effects can be increased when Tapentadol is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Tapentadol is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Tapentadol.
PerphenazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Tapentadol.
PhenelzineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Phenelzine.
PheniprazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pheniprazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Tapentadol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Tapentadol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Phenoxypropazine.
PhenterminePhentermine may increase the analgesic activities of Tapentadol.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Tapentadol.
PimozideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Tapentadol.
PipotiazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pipotiazine.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Tapentadol.
PiretanideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pirlindole.
PivhydrazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Tapentadol.
PolythiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pomalidomide.
PotassiumThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium Citrate.
PramipexoleTapentadol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Tapentadol.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Tapentadol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Tapentadol.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Tapentadol.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Tapentadol.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Tapentadol.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Tapentadol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Tapentadol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Tapentadol.
PromazinePromazine may increase the hypotensive activities of Tapentadol.
PromazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Tapentadol.
PromethazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Promethazine.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Tapentadol.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Tapentadol.
PropericiazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Propericiazine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Tapentadol.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Tapentadol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tapentadol.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Tapentadol.
PyrimethamineThe metabolism of Tapentadol can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Tapentadol.
QuetiapineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Quetiapine.
QuinethazoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Tapentadol.
QuinineThe metabolism of Tapentadol can be decreased when combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Tapentadol.
RamosetronTapentadol may increase the constipating activities of Ramosetron.
RanolazineThe metabolism of Tapentadol can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Rasagiline.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tapentadol.
RemoxiprideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Reserpine.
RifampicinThe metabolism of Tapentadol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Tapentadol can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Risperidone.
RitonavirThe metabolism of Tapentadol can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Tapentadol.
RolapitantThe metabolism of Tapentadol can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Tapentadol.
RopiniroleTapentadol may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Tapentadol can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Tapentadol.
RotigotineTapentadol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Tapentadol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Tapentadol.
SafrazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Safrazine.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Tapentadol.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tapentadol.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Tapentadol.
SelegilineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Tapentadol is combined with Sertindole.
SertralineTapentadol may increase the serotonergic activities of Sertraline.
SertralineThe metabolism of Tapentadol can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tapentadol.
SildenafilThe metabolism of Tapentadol can be decreased when combined with Sildenafil.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Tapentadol.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Tapentadol.
SorafenibThe metabolism of Tapentadol can be decreased when combined with Sorafenib.
SpironolactoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Tapentadol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tapentadol.
SulfadiazineThe metabolism of Tapentadol can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Tapentadol can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Tapentadol can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Tapentadol.
SuvorexantThe risk or severity of adverse effects can be increased when Tapentadol is combined with Suvorexant.
TasimelteonThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Tapentadol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tedizolid Phosphate.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Tapentadol.
TerbinafineThe metabolism of Tapentadol can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Tapentadol.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Tapentadol.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Tapentadol.
ThalidomideTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Tapentadol.
TheobromineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Theobromine.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tapentadol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Tapentadol.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Tapentadol.
ThioproperazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Tapentadol.
ThioridazineThioridazine may increase the hypotensive activities of Tapentadol.
ThiothixeneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Tapentadol.
TicagrelorThe metabolism of Tapentadol can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Tapentadol can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Tapentadol.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Tapentadol.
TipranavirThe metabolism of Tapentadol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Tapentadol.
TolbutamideThe metabolism of Tapentadol can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Tapentadol.
ToloxatoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Toloxatone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Tapentadol.
TolvaptanThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Tapentadol.
TorasemideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Tapentadol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Tranylcypromine.
TranylcypromineThe metabolism of Tapentadol can be decreased when combined with Tranylcypromine.
TrazodoneTapentadol may increase the serotonergic activities of Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Tapentadol.
TriamtereneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Tapentadol.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Tapentadol.
TrifluoperazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Tapentadol.
TriflupromazineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Tapentadol.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Tapentadol.
TrimethoprimThe metabolism of Tapentadol can be decreased when combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Tapentadol.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Tapentadol.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Tapentadol.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Tapentadol.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Tapentadol.
UlaritideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ularitide.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Tapentadol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Tapentadol.
ValsartanThe metabolism of Tapentadol can be decreased when combined with Valsartan.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tapentadol.
VenlafaxineThe metabolism of Tapentadol can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Venlafaxine.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Tapentadol.
VilazodoneTapentadol may increase the serotonergic activities of Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Tapentadol.
VoriconazoleThe metabolism of Tapentadol can be decreased when combined with Voriconazole.
VortioxetineTapentadol may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tapentadol.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Tapentadol.
ZafirlukastThe metabolism of Tapentadol can be decreased when combined with Zafirlukast.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Tapentadol.
ZiconotideThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ziconotide.
ZimelidineTapentadol may increase the serotonergic activities of Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Tapentadol is combined with Ziprasidone.
ZiprasidoneThe metabolism of Tapentadol can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Tapentadol.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tapentadol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Tapentadol.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Tapentadol.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Tapentadol.
ZotepineThe risk or severity of adverse effects can be increased when Tapentadol is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Zuclopenthixol.
Food Interactions
  • Food increases the AUC and Cmax of tapentadol. Despite this, tapentadol can be given without regards to food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Tzschentke TM, Christoph T, Kogel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J: (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007 Oct;323(1):265-76. Epub 2007 Jul 26. [PubMed:17656655 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Raffa RB, Buschmann H, Christoph T, Eichenbaum G, Englberger W, Flores CM, Hertrampf T, Kogel B, Schiene K, Strassburger W, Terlinden R, Tzschentke TM: Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother. 2012 Jul;13(10):1437-49. doi: 10.1517/14656566.2012.696097. Epub 2012 Jun 15. [PubMed:22698264 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Kneip C, Terlinden R, Beier H, Chen G: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008 Jan;2(1):67-75. [PubMed:19356073 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:17 / Updated on September 25, 2016 02:16